The present invention relates to pre-formulations comprising:a) at least one di-acyl lipid；b) at least one phospholipid；c) at least one biocompatible, organic solvent；d) an alkyl ammonium EDTA salt； ande) at least one somatostatin receptor agonist；wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %.The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.
